Literature DB >> 20421394

Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.

C García-de-la-Mària1, F Marco, Y Armero, D Soy, A Moreno, A del Río, M Almela, C Cervera, S Ninot, C Falces, C A Mestres, J M Gatell, M T Jiménez de Anta, J M Miró.   

Abstract

This study evaluated the daptomycin activity against two methicillin-resistant Staphylococcus epidermidis (MRSE) clinical isolates with different vancomycin susceptibilities: MRSE-375, with a vancomycin MIC of 2 microg/ml, and NRS6, a glycopeptide-intermediate S. epidermidis (GISE) strain with a vancomycin MIC of 8 microg/ml. The in vivo activity of daptomycin at two different doses (standard dose [SD-daptomycin], 6 mg/kg of body weight/day intravenously [i.v.]; high dose [HD-daptomycin], 10 mg/kg/day i.v.) was evaluated in a rabbit model of infective endocarditis and compared with that of a standard dose of vancomycin (SD-vancomycin; 1 g i.v. every 12 h) for 2 days. For the MRSE-375 strain, high-dose vancomycin (HD-vancomycin; 1 g i.v. every 6 h) was also studied. For MRSE-375, SD- and HD-daptomycin therapy sterilized significantly more vegetations than SD-vancomycin therapy (9/15 [60%] and 11/15 [73%] vegetations, respectively, versus 3/16 [19%] vegetations; P = 0.02 and P = 0.002, respectively). HD-daptomycin sterilized more vegetations than HD-vancomycin (11/15 [73%] versus 5/15 [33%] vegetations; P = 0.03) and was more effective than SD- and HD-vancomycin in reducing the density of bacteria in valve vegetations (0 log(10) CFU/g vegetation [interquartile range {IQR}, 0 to 1 log(10) CFU/g vegetation] versus 2 log(10) CFU/g vegetation [IQR, 2 to 2 log(10) CFU/g vegetation] and 2 log(10) CFU/g vegetation [IQR, 0 to 2.8 log(10) CFU/g vegetation]; P = 0.002 and P = 0.01, respectively). For the NRS6 strain, SD- and HD-daptomycin were significantly more effective than vancomycin in reducing the density of bacteria in valve vegetations (3.7 log(10) CFU/g vegetation [IQR, 2 to 6 log(10) CFU/g vegetation] versus 7.1 log(10) CFU/g vegetation [IQR, 5.2 to 8.5 log(10) CFU/g vegetation]; P = 0.02). In all treatment arms, isolates recovered from vegetations remained susceptible to daptomycin and vancomycin and had the same MICs. In conclusion, daptomycin at doses of 6 mg/kg/day or 10 mg/kg/day is more effective than vancomycin for the treatment of experimental endocarditis due to MRSE and GISE.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20421394      PMCID: PMC2897304          DOI: 10.1128/AAC.01011-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

Review 1.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Am J Health Syst Pharm       Date:  2009-01-01       Impact factor: 2.637

Review 2.  Diagnosis and management of staphylococcal infections of pacemakers and cardiac defibrillators.

Authors:  S T Chambers
Journal:  Intern Med J       Date:  2005-12       Impact factor: 2.048

3.  Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America.

Authors:  Larry M Baddour; Walter R Wilson; Arnold S Bayer; Vance G Fowler; Ann F Bolger; Matthew E Levison; Patricia Ferrieri; Michael A Gerber; Lloyd Y Tani; Michael H Gewitz; David C Tong; James M Steckelberg; Robert S Baltimore; Stanford T Shulman; Jane C Burns; Donald A Falace; Jane W Newburger; Thomas J Pallasch; Masato Takahashi; Kathryn A Taubert
Journal:  Circulation       Date:  2005-06-14       Impact factor: 29.690

4.  A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital.

Authors:  M Wootton; R A Howe; R Hillman; T R Walsh; P M Bennett; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  2001-04       Impact factor: 5.790

5.  The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis.

Authors:  D O Garrett; E Jochimsen; K Murfitt; B Hill; S McAllister; P Nelson; R V Spera; R K Sall; F C Tenover; J Johnston; B Zimmer; W R Jarvis
Journal:  Infect Control Hosp Epidemiol       Date:  1999-03       Impact factor: 3.254

6.  Coagulase-negative staphylococcal prosthetic valve endocarditis--a contemporary update based on the International Collaboration on Endocarditis: prospective cohort study.

Authors:  V H Chu; J M Miro; B Hoen; C H Cabell; P A Pappas; P Jones; M E Stryjewski; I Anguera; S Braun; P Muñoz; P Commerford; P Tornos; J Francis; M Oyonarte; C Selton-Suty; A J Morris; G Habib; B Almirante; D J Sexton; G R Corey; V G Fowler
Journal:  Heart       Date:  2008-10-24       Impact factor: 5.994

7.  Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study.

Authors:  David R Murdoch; G Ralph Corey; Bruno Hoen; José M Miró; Vance G Fowler; Arnold S Bayer; Adolf W Karchmer; Lars Olaison; Paul A Pappas; Philippe Moreillon; Stephen T Chambers; Vivian H Chu; Vicenç Falcó; David J Holland; Philip Jones; John L Klein; Nigel J Raymond; Kerry M Read; Marie Francoise Tripodi; Riccardo Utili; Andrew Wang; Christopher W Woods; Christopher H Cabell
Journal:  Arch Intern Med       Date:  2009-03-09

8.  Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.

Authors:  José M Miró; Cristina García-de-la-Mària; Yolanda Armero; Elisa de-Lazzari; Dolors Soy; Asunción Moreno; Ana del Rio; Manel Almela; Carlos A Mestres; José M Gatell; María-Teresa Jiménez-de-Anta; Francesc Marco
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

9.  Emergence of coagulase-negative staphylococci as a cause of native valve endocarditis.

Authors:  Vivian H Chu; Christopher W Woods; Jose M Miro; Bruno Hoen; Christopher H Cabell; Paul A Pappas; Jerome Federspiel; Eugene Athan; Martin E Stryjewski; Francisco Nacinovich; Francesc Marco; Donald P Levine; Tom S Elliott; Claudio Q Fortes; Pilar Tornos; David L Gordon; Riccardo Utili; Francois Delahaye; G Ralph Corey; Vance G Fowler
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

10.  Daptomycin in the treatment of bacteremia.

Authors:  George Sakoulas; Yoav Golan; Kenneth C Lamp; Lawrence V Friedrich; Rene Russo
Journal:  Am J Med       Date:  2007-10       Impact factor: 4.965

View more
  5 in total

1.  Efficacy of daptomycin versus vancomycin in an experimental model of foreign-body and systemic infection caused by biofilm producers and methicillin-resistant Staphylococcus epidermidis.

Authors:  J Domínguez-Herrera; F Docobo-Pérez; R López-Rojas; C Pichardo; R Ruiz-Valderas; J A Lepe; J Pachón
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

2.  Daptomycin concentrations in valve tissue and vegetation in patients with bacterial endocarditis.

Authors:  Carlo Tascini; Antonello Di Paolo; Roberta Poletti; Sarah Flammini; Michele Emdin; Ilaria Ciullo; Enrico Tagliaferri; Annette Moter; Francesco Menichetti
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191

3.  Successful salvage therapy with Daptomycin for osteomyelitis caused by methicillin-resistant Staphylococcus aureus in a renal transplant recipient with Fabry-Anderson disease.

Authors:  Ennio Polilli; Tamara Ursini; Elena Mazzotta; Federica Sozio; Vincenzo Savini; Domenico D'Antonio; Michelino Barbato; Augusta Consorte; Giustino Parruti
Journal:  Ann Clin Microbiol Antimicrob       Date:  2012-03-11       Impact factor: 3.944

4.  Epidemiology and prognosis of coagulase-negative staphylococcal endocarditis: impact of vancomycin minimum inhibitory concentration.

Authors:  Cristina García de la Mària; Carlos Cervera; Juan M Pericàs; Ximena Castañeda; Yolanda Armero; Dolors Soy; Manel Almela; Salvador Ninot; Carlos Falces; Carlos A Mestres; Jose M Gatell; Asuncion Moreno; Francesc Marco; José M Miró
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

Review 5.  Successful management of a complicated clinical crisis: A patient with left-sided endocarditis and secondary hemophagocytic lymphohistiocytosis: a rare case report and literature review.

Authors:  Peipei Xu; Hui Zeng; Min Zhou; Jian Ouyang; Bing Chen; Qiguo Zhang
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.